Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Zenagamtide s.c. Once-weekly in Asian Participants With Overweight or Obesity (AMAZE 13)

NCT07668401 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT07668401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07668401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Zenagamtide s.c. Once-weekly in Asian Participants With Overweight or Obesity (AMAZE 13)
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Not yet recruiting
Start date
January 7, 2027
Completion date
January 11, 2029
Enrollment
400 (estimated)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight